Abstract 4565
Background
The residual disease (RD) after debulking surgery is one of the strongest prognostic factors in ovarian cancer (OC) patients. Despite surgical efforts, most patients do not achieve "optimal" cytoreduction (R0) even in high-volume centres. The interplay between cancer-promoted angiogenesis and host immune-system could foster cancer dissemination, reducing the likelihood of surgical eradication. The aim of this study was to assess whether the presence of germline polymorphisms in genes involved in angiogenesis and immunity pathways was predictive of R0.
Methods
A cohort of 230 patients with stage III-IV, high grade epithelial OC treated with debulking surgery and platinum-based therapy without bevacizumab, was retrospectively enrolled. A panel of 192 single nucleotide polymorphisms (SNPs) in 34 angiogenesis and immune system-related genes was analyzed with Illumina GoldenGate Genotyping Assay. Log-additive, dominant and recessive genetic models were evaluated using a multivariate logistic regression adjusted for type of surgery (i.e. primary or interval). False discovery rate (FDR) test<0.2 was used for multiple testing data correction.
Results
Thirteen SNPs were significantly associated with RD. Among them, MMP3-rs569444, TLR3-rs5743303 and VEGFA-rs2146323 passed the FDR filter. Patients carrying the variant alleles of MMP3-rs569444 (OR = 2.52, 95%CI 1.42-4.47, p = 0.0326) and VEGFA-rs2146323 (OR = 1.83, 95%CI 1.21-2.75, p = 0.0375) showed an increased risk of RD. Conversely, TLR3-rs5743303 carriers were more likely to achieve R0 (OR = 0.43, 95%CI 0.27-0.7, p = 0.0004).
Conclusions
Angiogenesis and the immune-system competence are key players in OC growth and could influence the burden of RD. In our cohort, individual polymorphisms on angiogenesis (VEGFA), extracellular matrix degradation (MMP3) and innate immunity activation (TLR3) pathways were independent predictive factors of RD. These markers, whether validated, might underline the role of host genetics factors in predicting R0. Moreover, if VEGFA-rs2146323 variant carriers could benefit the most from bevacizumab appears as an intriguing question.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Toffoli Giuseppe.
Funding
Has not received any funding.
Disclosure
F. Puglisi: Honoraria (self), Advisory / Consultancy: Amgen; Advisory / Consultancy: Celgene; Advisory / Consultancy: Eisai; Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: Ipsen; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self): Pierre Fabre; Advisory / Consultancy: Merck Sharp & Dohme; Advisory / Consultancy: Takeda; Research grant / Funding (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
3907 - Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR)
Presenter: Axel Grothey
Session: Poster Display session 2
Resources:
Abstract
3958 - Quality of Life (QoL) in Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results of a European Survey
Presenter: Zorana Maravic
Session: Poster Display session 2
Resources:
Abstract
3563 - BISQUIT: A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal
Presenter: Rachel Riechelmann
Session: Poster Display session 2
Resources:
Abstract
1184 - iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
Presenter: Fiona Turkes
Session: Poster Display session 2
Resources:
Abstract
3346 - Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study
Presenter: Lisa Salvatore
Session: Poster Display session 2
Resources:
Abstract
3895 - A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study.
Presenter: Maria Aurelia Barbera
Session: Poster Display session 2
Resources:
Abstract
2012 - Open Label Phase III Study of Arfolitixorin vs. Leucovorin in mFOLFOX-6 for First Line Treatment of Metastatic Colorectal Cancer: AGENT
Presenter: Josep Tabernero
Session: Poster Display session 2
Resources:
Abstract
2198 - SOLSTICE, a phase 3, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
Presenter: Thierry Andre
Session: Poster Display session 2
Resources:
Abstract
2921 - A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable (MSS) Colorectal Carcinoma (short title CAROSELL)
Presenter: Mark Saunders
Session: Poster Display session 2
Resources:
Abstract
3695 - A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation
Presenter: Heinz Josef Lenz
Session: Poster Display session 2
Resources:
Abstract